These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12084605)

  • 1. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
    McClean DR; Ikram H; Mehta S; Heywood JT; Rousseau MF; Niederman AL; Sequeira RF; Fleck E; Singh SN; Coutu B; Hanrath P; Komajda M; Bryson CC; Qian C; Hanyok JJ;
    J Am Coll Cardiol; 2002 Jun; 39(12):2034-41. PubMed ID: 12084605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.
    McClean DR; Ikram H; Garlick AH; Richards AM; Nicholls MG; Crozier IG
    J Am Coll Cardiol; 2000 Aug; 36(2):479-86. PubMed ID: 10933361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
    Sheth T; Parker T; Block A; Hall C; Adam A; Pfeffer MA; Stewart DJ; Qian C; Rouleau JL;
    Am J Cardiol; 2002 Sep; 90(5):496-500. PubMed ID: 12208409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
    Klapholz M; Thomas I; Eng C; Iteld BJ; Ponce GA; Niederman AL; Bilsker M; Heywood JT; Synhorst D
    Am J Cardiol; 2001 Sep; 88(6):657-61. PubMed ID: 11564390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
    Maniu CV; Meyer DM; Redfield MM
    Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
    Troughton RW; Rademaker MT; Powell JD; Yandle TG; Espiner EA; Frampton CM; Nicholls MG; Richards AM
    Hypertension; 2000 Oct; 36(4):523-30. PubMed ID: 11040230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
    Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
    Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease.
    Neal B; MacMahon S; Ohkubo T; Brnabic A; Tonkin A;
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):270-6. PubMed ID: 12584671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study.
    Mitchell GF; Izzo JL; Lacourcière Y; Ouellet JP; Neutel J; Qian C; Kerwin LJ; Block AJ; Pfeffer MA
    Circulation; 2002 Jun; 105(25):2955-61. PubMed ID: 12081987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
    Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
    Nathisuwan S; Talbert RL
    Pharmacotherapy; 2002 Jan; 22(1):27-42. PubMed ID: 11794428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
    Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
    Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
    Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
    Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
    Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
    Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
    Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
    Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of omapatrilat on systemic arterial function in patients with chronic heart failure.
    McClean DR; Ikram H; Garlick AH; Crozier IG
    Am J Cardiol; 2001 Mar; 87(5):565-9. PubMed ID: 11230840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.